EPO mRNA encodes the human erythropoietin (EPO) protein, a hormone that controls erythropoiesis, or red blood cell production. EPO also plays a role in wound healing and the brain’s response to neural injury. Kariko et al. showed that transfection of EPO mRNA in vivo resulted in significant increases of both reticulocyte counts and hematocrits.

• Capped with CleanCap® M6 cap analog, modified with N1-methylpseudouridines to enhance protein expression
• Cap 1 structure with >95% capping efficiency for superior in vivo activity compared to Cap-0 mRNAs
• Manufactured with CleanCap M6–specific IVT that lowers dsRNA and improves performance
• Ready to use in downstream mRNA applications and formulations
• Grade: RUO

This mRNA is capped using CleanCap® Reagent M6, TriLink’s patented co-transcriptional capping technology, resulting in the naturally occurring Cap-1 structure with >95% capping efficiency. It is polyadenylated, modified with N1-methylpseudouridine, and optimised for mammalian systems. It mimics a fully processed mature mRNA.

CleanCap Reagent M6, otherwise known as CleanCap m6AG 3′ OMe, produces a base-modified Cap-1 mRNA, which shows superior in vivo activity compared to Cap-0 mRNA produced by legacy capping methods such as mCap or anti-reverse cap analog (ARCA). CleanCap M6 may further increase protein expression relative to previous generations of cap analogs, such as CleanCap AG or CleanCap AG (3′ OMe), or mRNAs produced by enzymatic capping strategies.

N1-methylpseudouridine is a modified uridine that can reduce immunogenic response and enhance translational efficiency of mRNAs. These properties can result in safer mRNA and increased protein expression.